{"transactions":[{"id":3483925,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":156027,"kind":"organization","name":"QVT Associates GP LLC","position":1,"cik":"0001290166","reported_name":"QVT Associates GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":156029,"kind":"organization","name":"QVT Financial Investment Cayman Ltd.","position":2,"cik":"0001771138","reported_name":"QVT Financial Investment Cayman Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-06-19T18:52:17.000Z","date":"2019-06-19","kind":"purchase","acquired":true,"shares":4957,"price":8.1693,"value":40495.2201,"ownership":{"direct":false,"nature":"(see fn5)"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the \"Exchange Act\") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.00 to $8.27, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, \"QVT\"), may be deemed to have beneficial ownership over the 22,860,013 Common Shares held by Roivant Sciences Ltd. (\"Roivant\") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":22860013,"source":{"system":"sec-edgar","filing":"0000899243-19-017480","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1290166/000089924319017480/doc4.xml","form_type":"4"}},{"id":3483924,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":156027,"kind":"organization","name":"QVT Associates GP LLC","position":1,"cik":"0001290166","reported_name":"QVT Associates GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":156029,"kind":"organization","name":"QVT Financial Investment Cayman Ltd.","position":2,"cik":"0001771138","reported_name":"QVT Financial Investment Cayman Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-06-19T18:52:17.000Z","date":"2019-06-18","kind":"purchase","acquired":true,"shares":6706,"price":8.2107,"value":55060.9542,"ownership":{"direct":false,"nature":"(see fn5)"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the \"Exchange Act\") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.09 to $8.29, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, \"QVT\"), may be deemed to have beneficial ownership over the 22,860,013 Common Shares held by Roivant Sciences Ltd. (\"Roivant\") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":22855056,"source":{"system":"sec-edgar","filing":"0000899243-19-017480","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1290166/000089924319017480/doc4.xml","form_type":"4"}},{"id":3483923,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":156027,"kind":"organization","name":"QVT Associates GP LLC","position":1,"cik":"0001290166","reported_name":"QVT Associates GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":156029,"kind":"organization","name":"QVT Financial Investment Cayman Ltd.","position":2,"cik":"0001771138","reported_name":"QVT Financial Investment Cayman Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-06-19T18:52:17.000Z","date":"2019-06-17","kind":"purchase","acquired":true,"shares":6541,"price":8.5346,"value":55824.8186,"ownership":{"direct":false,"nature":"(see fn5)"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the \"Exchange Act\") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.11 to $8.70, inclusive. The reporting person undertakes to provide to Urovant Sciences Ltd. (\"Urovant\"), any security holder of Urovant, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, \"QVT\"), may be deemed to have beneficial ownership over the 22,860,013 Common Shares held by Roivant Sciences Ltd. (\"Roivant\") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":22848350,"source":{"system":"sec-edgar","filing":"0000899243-19-017480","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290166/000089924319017480/doc4.xml","form_type":"4"}},{"id":3489399,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":156027,"kind":"organization","name":"QVT Associates GP LLC","position":1,"cik":"0001290166","reported_name":"QVT Associates GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":156029,"kind":"organization","name":"QVT Financial Investment Cayman Ltd.","position":2,"cik":"0001771138","reported_name":"QVT Financial Investment Cayman Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-06-14T18:16:23.000Z","date":"2019-06-14","kind":"purchase","acquired":true,"shares":7144,"price":7.9107,"value":56514.0408,"ownership":{"direct":false,"nature":"(see fn5)"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the \"Exchange Act\") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.65 to $8.00, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, \"QVT\"), may be deemed to have beneficial ownership over the 22,841,809 Common Shares held by Roivant Sciences Ltd. (\"Roivant\") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":22841809,"source":{"system":"sec-edgar","filing":"0000899243-19-017094","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1290166/000089924319017094/doc4.xml","form_type":"4"}},{"id":3489398,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":156027,"kind":"organization","name":"QVT Associates GP LLC","position":1,"cik":"0001290166","reported_name":"QVT Associates GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":156029,"kind":"organization","name":"QVT Financial Investment Cayman Ltd.","position":2,"cik":"0001771138","reported_name":"QVT Financial Investment Cayman Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-06-14T18:16:23.000Z","date":"2019-06-13","kind":"purchase","acquired":true,"shares":7367,"price":7.9466,"value":58542.6022,"ownership":{"direct":false,"nature":"(see fn5)"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the \"Exchange Act\") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.67 to $8.39, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, \"QVT\"), may be deemed to have beneficial ownership over the 22,841,809 Common Shares held by Roivant Sciences Ltd. (\"Roivant\") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":22834665,"source":{"system":"sec-edgar","filing":"0000899243-19-017094","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1290166/000089924319017094/doc4.xml","form_type":"4"}},{"id":3489397,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":156027,"kind":"organization","name":"QVT Associates GP LLC","position":1,"cik":"0001290166","reported_name":"QVT Associates GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":156029,"kind":"organization","name":"QVT Financial Investment Cayman Ltd.","position":2,"cik":"0001771138","reported_name":"QVT Financial Investment Cayman Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-06-14T18:16:23.000Z","date":"2019-06-12","kind":"purchase","acquired":true,"shares":7500,"price":8.2992,"value":62244.0,"ownership":{"direct":false,"nature":"(see fn5)"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the \"Exchange Act\") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.16 to $8.77, inclusive. The reporting person undertakes to provide to Urovant Sciences Ltd. (\"Urovant\"), any security holder of Urovant, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, \"QVT\"), may be deemed to have beneficial ownership over the 22,841,809 Common Shares held by Roivant Sciences Ltd. (\"Roivant\") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":22827298,"source":{"system":"sec-edgar","filing":"0000899243-19-017094","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290166/000089924319017094/doc4.xml","form_type":"4"}},{"id":3494038,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":156027,"kind":"organization","name":"QVT Associates GP LLC","position":1,"cik":"0001290166","reported_name":"QVT Associates GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":156029,"kind":"organization","name":"QVT Financial Investment Cayman Ltd.","position":2,"cik":"0001771138","reported_name":"QVT Financial Investment Cayman Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-06-11T19:05:32.000Z","date":"2019-06-11","kind":"purchase","acquired":true,"shares":7189,"price":8.5817,"value":61693.8413,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the \"Exchange Act\") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.41 to $8.75, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, \"QVT\"), may be deemed to have beneficial ownership over the 22,819,798 Common Shares held by Roivant Sciences Ltd. (\"Roivant\") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":22819798,"source":{"system":"sec-edgar","filing":"0000899243-19-016511","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1290166/000089924319016511/doc4.xml","form_type":"4"}},{"id":3494037,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":156027,"kind":"organization","name":"QVT Associates GP LLC","position":1,"cik":"0001290166","reported_name":"QVT Associates GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":156029,"kind":"organization","name":"QVT Financial Investment Cayman Ltd.","position":2,"cik":"0001771138","reported_name":"QVT Financial Investment Cayman Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-06-11T19:05:32.000Z","date":"2019-06-10","kind":"purchase","acquired":true,"shares":7500,"price":8.3459,"value":62594.25,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the \"Exchange Act\") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.89 to $8.68, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, \"QVT\"), may be deemed to have beneficial ownership over the 22,819,798 Common Shares held by Roivant Sciences Ltd. (\"Roivant\") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":22812609,"source":{"system":"sec-edgar","filing":"0000899243-19-016511","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1290166/000089924319016511/doc4.xml","form_type":"4"}},{"id":3494036,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":156027,"kind":"organization","name":"QVT Associates GP LLC","position":1,"cik":"0001290166","reported_name":"QVT Associates GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":156029,"kind":"organization","name":"QVT Financial Investment Cayman Ltd.","position":2,"cik":"0001771138","reported_name":"QVT Financial Investment Cayman Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-06-11T19:05:32.000Z","date":"2019-06-07","kind":"purchase","acquired":true,"shares":6649,"price":7.965,"value":52959.285,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the \"Exchange Act\") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.73 to $8.10, inclusive. The reporting person undertakes to provide to Urovant Sciences Ltd. (\"Urovant\"), any security holder of Urovant, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, \"QVT\"), may be deemed to have beneficial ownership over the 22,819,798 Common Shares held by Roivant Sciences Ltd. (\"Roivant\") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":22805109,"source":{"system":"sec-edgar","filing":"0000899243-19-016511","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290166/000089924319016511/doc4.xml","form_type":"4"}},{"id":3498698,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":156027,"kind":"organization","name":"QVT Associates GP LLC","position":1,"cik":"0001290166","reported_name":"QVT Associates GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":156029,"kind":"organization","name":"QVT Financial Investment Cayman Ltd.","position":2,"cik":"0001771138","reported_name":"QVT Financial Investment Cayman Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-06-06T20:57:03.000Z","date":"2019-06-06","kind":"purchase","acquired":true,"shares":7082,"price":7.9951,"value":56621.2982,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the \"Exchange Act\") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.73 to $8.57, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, \"QVT\"), may be deemed to have beneficial ownership over the 22,798,460 Common Shares held by Roivant Sciences Ltd. (\"Roivant\") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":22798460,"source":{"system":"sec-edgar","filing":"0000899243-19-015910","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1290166/000089924319015910/doc4.xml","form_type":"4"}},{"id":3498697,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":156027,"kind":"organization","name":"QVT Associates GP LLC","position":1,"cik":"0001290166","reported_name":"QVT Associates GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":156029,"kind":"organization","name":"QVT Financial Investment Cayman Ltd.","position":2,"cik":"0001771138","reported_name":"QVT Financial Investment Cayman Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-06-06T20:57:03.000Z","date":"2019-06-05","kind":"purchase","acquired":true,"shares":6540,"price":8.015,"value":52418.1,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the \"Exchange Act\") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.68 to $8.33, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, \"QVT\"), may be deemed to have beneficial ownership over the 22,798,460 Common Shares held by Roivant Sciences Ltd. (\"Roivant\") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":22791378,"source":{"system":"sec-edgar","filing":"0000899243-19-015910","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1290166/000089924319015910/doc4.xml","form_type":"4"}},{"id":3498696,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":156027,"kind":"organization","name":"QVT Associates GP LLC","position":1,"cik":"0001290166","reported_name":"QVT Associates GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":156029,"kind":"organization","name":"QVT Financial Investment Cayman Ltd.","position":2,"cik":"0001771138","reported_name":"QVT Financial Investment Cayman Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-06-06T20:57:03.000Z","date":"2019-06-04","kind":"purchase","acquired":true,"shares":7500,"price":7.5881,"value":56910.75,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the \"Exchange Act\") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.42 to $7.71, inclusive. The reporting person undertakes to provide to Urovant Sciences Ltd. (\"Urovant\"), any security holder of Urovant, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, \"QVT\"), may be deemed to have beneficial ownership over the 22,798,460 Common Shares held by Roivant Sciences Ltd. (\"Roivant\") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":22784838,"source":{"system":"sec-edgar","filing":"0000899243-19-015910","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290166/000089924319015910/doc4.xml","form_type":"4"}},{"id":3498695,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":156027,"kind":"organization","name":"QVT Associates GP LLC","position":1,"cik":"0001290166","reported_name":"QVT Associates GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":156028,"kind":"person","name":"QVT Fund V LP","position":2,"cik":"0001543904","reported_name":"QVT Fund V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, $0.000017727 par value per share","published_at":"2019-06-06T20:05:17.000Z","date":"2019-06-04","kind":"purchase","acquired":true,"shares":2424242,"price":8.25,"value":19999996.5,"ownership":{"direct":false,"nature":"see fn"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, \"QVT\"), may be deemed to have beneficial ownership over the 40,765,599 Common Shares held by Roivant Sciences Ltd. (\"Roivant\") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":40765599,"source":{"system":"sec-edgar","filing":"0000899243-19-015895","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290166/000089924319015895/doc4.xml","form_type":"4"}},{"id":3504449,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":156027,"kind":"organization","name":"QVT Associates GP LLC","position":1,"cik":"0001290166","reported_name":"QVT Associates GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":156029,"kind":"organization","name":"QVT Financial Investment Cayman Ltd.","position":2,"cik":"0001771138","reported_name":"QVT Financial Investment Cayman Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-06-03T18:18:20.000Z","date":"2019-06-03","kind":"purchase","acquired":true,"shares":5424,"price":7.7092,"value":41814.7008,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the \"Exchange Act\") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.64 to $7.74, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, \"QVT\"), may be deemed to have beneficial ownership over the 22,777,338 Common Shares held by Roivant Sciences Ltd. (\"Roivant\") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":22777338,"source":{"system":"sec-edgar","filing":"0000899243-19-015402","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1290166/000089924319015402/doc4.xml","form_type":"4"}},{"id":3504448,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":156027,"kind":"organization","name":"QVT Associates GP LLC","position":1,"cik":"0001290166","reported_name":"QVT Associates GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":156029,"kind":"organization","name":"QVT Financial Investment Cayman Ltd.","position":2,"cik":"0001771138","reported_name":"QVT Financial Investment Cayman Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-06-03T18:18:20.000Z","date":"2019-05-31","kind":"purchase","acquired":true,"shares":5071,"price":7.6991,"value":39042.1361,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the \"Exchange Act\") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.41 to $7.84, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, \"QVT\"), may be deemed to have beneficial ownership over the 22,777,338 Common Shares held by Roivant Sciences Ltd. (\"Roivant\") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":22771914,"source":{"system":"sec-edgar","filing":"0000899243-19-015402","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1290166/000089924319015402/doc4.xml","form_type":"4"}},{"id":3504447,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":156027,"kind":"organization","name":"QVT Associates GP LLC","position":1,"cik":"0001290166","reported_name":"QVT Associates GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":156029,"kind":"organization","name":"QVT Financial Investment Cayman Ltd.","position":2,"cik":"0001771138","reported_name":"QVT Financial Investment Cayman Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-06-03T18:18:20.000Z","date":"2019-05-30","kind":"purchase","acquired":true,"shares":300,"price":8.9066,"value":2671.98,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the \"Exchange Act\") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.71 to $9.03, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, \"QVT\"), may be deemed to have beneficial ownership over the 22,777,338 Common Shares held by Roivant Sciences Ltd. (\"Roivant\") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":22766843,"source":{"system":"sec-edgar","filing":"0000899243-19-015402","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1290166/000089924319015402/doc4.xml","form_type":"4"}},{"id":3504446,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":156027,"kind":"organization","name":"QVT Associates GP LLC","position":1,"cik":"0001290166","reported_name":"QVT Associates GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":156029,"kind":"organization","name":"QVT Financial Investment Cayman Ltd.","position":2,"cik":"0001771138","reported_name":"QVT Financial Investment Cayman Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-06-03T18:18:20.000Z","date":"2019-05-30","kind":"purchase","acquired":true,"shares":6951,"price":7.9726,"value":55417.5426,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the \"Exchange Act\") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.70 to $8.70, inclusive. The reporting person undertakes to provide to Urovant Sciences Ltd. (\"Urovant\"), any security holder of Urovant, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, \"QVT\"), may be deemed to have beneficial ownership over the 22,777,338 Common Shares held by Roivant Sciences Ltd. (\"Roivant\") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":22766543,"source":{"system":"sec-edgar","filing":"0000899243-19-015402","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290166/000089924319015402/doc4.xml","form_type":"4"}},{"id":3508584,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":156027,"kind":"organization","name":"QVT Associates GP LLC","position":1,"cik":"0001290166","reported_name":"QVT Associates GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":156029,"kind":"organization","name":"QVT Financial Investment Cayman Ltd.","position":2,"cik":"0001771138","reported_name":"QVT Financial Investment Cayman Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-05-29T18:05:44.000Z","date":"2019-05-29","kind":"purchase","acquired":true,"shares":6882,"price":7.5535,"value":51983.187,"ownership":{"direct":false,"nature":"(see fn5)"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.40 to $7.69, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, \"QVT\"), may be deemed to have beneficial ownership over the 22,759,592 Common Shares held by Roivant because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein"}],"balance_after":22759592,"source":{"system":"sec-edgar","filing":"0000899243-19-015062","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1290166/000089924319015062/doc4.xml","form_type":"4"}},{"id":3508583,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":156027,"kind":"organization","name":"QVT Associates GP LLC","position":1,"cik":"0001290166","reported_name":"QVT Associates GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":156029,"kind":"organization","name":"QVT Financial Investment Cayman Ltd.","position":2,"cik":"0001771138","reported_name":"QVT Financial Investment Cayman Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-05-29T18:05:44.000Z","date":"2019-05-28","kind":"purchase","acquired":true,"shares":3807,"price":7.6818,"value":29244.6126,"ownership":{"direct":false,"nature":"(see fn5)"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.65 to $7.70, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, \"QVT\"), may be deemed to have beneficial ownership over the 22,759,592 Common Shares held by Roivant because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein"}],"balance_after":22752710,"source":{"system":"sec-edgar","filing":"0000899243-19-015062","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1290166/000089924319015062/doc4.xml","form_type":"4"}},{"id":3508582,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":156027,"kind":"organization","name":"QVT Associates GP LLC","position":1,"cik":"0001290166","reported_name":"QVT Associates GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":156029,"kind":"organization","name":"QVT Financial Investment Cayman Ltd.","position":2,"cik":"0001771138","reported_name":"QVT Financial Investment Cayman Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-05-29T18:05:44.000Z","date":"2019-05-24","kind":"purchase","acquired":true,"shares":3796,"price":7.7011,"value":29233.3756,"ownership":{"direct":false,"nature":"(see fn5)"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.66 to $7.74, inclusive. The reporting person undertakes to provide to Urovant Sciences Ltd. (\"Urovant\"), any security holder of Urovant, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, \"QVT\"), may be deemed to have beneficial ownership over the 22,759,592 Common Shares held by Roivant because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein"}],"balance_after":22748903,"source":{"system":"sec-edgar","filing":"0000899243-19-015062","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290166/000089924319015062/doc4.xml","form_type":"4"}},{"id":3513241,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":156027,"kind":"organization","name":"QVT Associates GP LLC","position":1,"cik":"0001290166","reported_name":"QVT Associates GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":156029,"kind":"organization","name":"QVT Financial Investment Cayman Ltd.","position":2,"cik":"0001771138","reported_name":"QVT Financial Investment Cayman Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-05-23T18:26:08.000Z","date":"2019-05-23","kind":"purchase","acquired":true,"shares":4802,"price":7.7576,"value":37251.9952,"ownership":{"direct":false,"nature":"(see fn6)"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The transaction was a series of open market purchases made under a trading plan established pursuant to Rule 10b5-1 under the Exchange Act and in accordance with the safe harbor of Rule 10b-18."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.645 to $7.98, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, \"QVT\"), may be deemed to have beneficial ownership over the 22,745,107 Common Shares held by Roivant Sciences Ltd. (\"Roivant\") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":22745107,"source":{"system":"sec-edgar","filing":"0000899243-19-014556","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1290166/000089924319014556/doc4.xml","form_type":"4"}},{"id":3513240,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":156027,"kind":"organization","name":"QVT Associates GP LLC","position":1,"cik":"0001290166","reported_name":"QVT Associates GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":156029,"kind":"organization","name":"QVT Financial Investment Cayman Ltd.","position":2,"cik":"0001771138","reported_name":"QVT Financial Investment Cayman Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-05-23T18:26:08.000Z","date":"2019-05-22","kind":"purchase","acquired":true,"shares":5033,"price":8.0584,"value":40557.9272,"ownership":{"direct":false,"nature":"(see fn6)"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The transaction was a series of open market purchases made under a trading plan established pursuant to Rule 10b5-1 under the Exchange Act and in accordance with the safe harbor of Rule 10b-18."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.825 to $8.43, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, \"QVT\"), may be deemed to have beneficial ownership over the 22,745,107 Common Shares held by Roivant Sciences Ltd. (\"Roivant\") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":22740305,"source":{"system":"sec-edgar","filing":"0000899243-19-014556","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1290166/000089924319014556/doc4.xml","form_type":"4"}},{"id":3513239,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":156027,"kind":"organization","name":"QVT Associates GP LLC","position":1,"cik":"0001290166","reported_name":"QVT Associates GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":156029,"kind":"organization","name":"QVT Financial Investment Cayman Ltd.","position":2,"cik":"0001771138","reported_name":"QVT Financial Investment Cayman Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-05-23T18:26:08.000Z","date":"2019-05-21","kind":"purchase","acquired":true,"shares":9995,"price":8.5151,"value":85108.4245,"ownership":{"direct":false,"nature":"(see fn6)"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made in accordance with the safe harbor of Rule 10b-18 (\"Rule 10b-18\") under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.31 to $8.69, inclusive. The reporting person undertakes to provide to Urovant Sciences Ltd. (\"Urovant\"), any security holder of Urovant, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, \"QVT\"), may be deemed to have beneficial ownership over the 22,745,107 Common Shares held by Roivant Sciences Ltd. (\"Roivant\") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":22735272,"source":{"system":"sec-edgar","filing":"0000899243-19-014556","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290166/000089924319014556/doc4.xml","form_type":"4"}},{"id":3518257,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":156027,"kind":"organization","name":"QVT Associates GP LLC","position":1,"cik":"0001290166","reported_name":"QVT Associates GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":156029,"kind":"organization","name":"QVT Financial Investment Cayman Ltd.","position":2,"cik":"0001771138","reported_name":"QVT Financial Investment Cayman Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-05-20T18:32:40.000Z","date":"2019-05-20","kind":"purchase","acquired":true,"shares":1715,"price":8.3867,"value":14383.1905,"ownership":{"direct":false,"nature":"(see fn6)"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each transaction was a series of open market purchases made in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.36 to $8.47, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, \"QVT\"), may be deemed to have beneficial ownership over the 22,725,277 Common Shares held by Roivant Sciences Ltd. (\"Roivant\") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":22725277,"source":{"system":"sec-edgar","filing":"0000899243-19-014214","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1290166/000089924319014214/doc4.xml","form_type":"4"}},{"id":3518256,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":156027,"kind":"organization","name":"QVT Associates GP LLC","position":1,"cik":"0001290166","reported_name":"QVT Associates GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":156029,"kind":"organization","name":"QVT Financial Investment Cayman Ltd.","position":2,"cik":"0001771138","reported_name":"QVT Financial Investment Cayman Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-05-20T18:32:40.000Z","date":"2019-05-20","kind":"purchase","acquired":true,"shares":8285,"price":7.9833,"value":66141.6405,"ownership":{"direct":false,"nature":"(see fn6)"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each transaction was a series of open market purchases made in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.35 to $8.35, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, \"QVT\"), may be deemed to have beneficial ownership over the 22,725,277 Common Shares held by Roivant Sciences Ltd. (\"Roivant\") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":22723562,"source":{"system":"sec-edgar","filing":"0000899243-19-014214","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1290166/000089924319014214/doc4.xml","form_type":"4"}},{"id":3518255,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":156027,"kind":"organization","name":"QVT Associates GP LLC","position":1,"cik":"0001290166","reported_name":"QVT Associates GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":156029,"kind":"organization","name":"QVT Financial Investment Cayman Ltd.","position":2,"cik":"0001771138","reported_name":"QVT Financial Investment Cayman Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-05-20T18:32:40.000Z","date":"2019-05-17","kind":"purchase","acquired":true,"shares":6200,"price":7.3615,"value":45641.3,"ownership":{"direct":false,"nature":"(see fn6)"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each transaction was a series of open market purchases made in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.03 to $7.85, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, \"QVT\"), may be deemed to have beneficial ownership over the 22,725,277 Common Shares held by Roivant Sciences Ltd. (\"Roivant\") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":22715277,"source":{"system":"sec-edgar","filing":"0000899243-19-014214","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1290166/000089924319014214/doc4.xml","form_type":"4"}},{"id":3518254,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":156027,"kind":"organization","name":"QVT Associates GP LLC","position":1,"cik":"0001290166","reported_name":"QVT Associates GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":156029,"kind":"organization","name":"QVT Financial Investment Cayman Ltd.","position":2,"cik":"0001771138","reported_name":"QVT Financial Investment Cayman Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-05-20T18:32:40.000Z","date":"2019-05-16","kind":"purchase","acquired":true,"shares":5408,"price":6.7896,"value":36718.1568,"ownership":{"direct":false,"nature":"(see fn6)"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each transaction was a series of open market purchases made in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $6.70 to $6.93, inclusive. The reporting person undertakes to provide to Urovant Sciences Ltd. (\"Urovant\"), any security holder of Urovant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, \"QVT\"), may be deemed to have beneficial ownership over the 22,725,277 Common Shares held by Roivant Sciences Ltd. (\"Roivant\") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":22709077,"source":{"system":"sec-edgar","filing":"0000899243-19-014214","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290166/000089924319014214/doc4.xml","form_type":"4"}},{"id":3586213,"issuer":{"id":130622,"kind":"organization","name":"Sio Gene Therapies Inc.","symbol":"SIOX"},"owners":[{"id":156027,"kind":"organization","name":"QVT Associates GP LLC","position":1,"cik":"0001290166","reported_name":"QVT Associates GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":156029,"kind":"organization","name":"QVT Financial Investment Cayman Ltd.","position":2,"cik":"0001771138","reported_name":"QVT Financial Investment Cayman Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, $0.00001 par value per share","published_at":"2019-03-19T17:15:55.000Z","date":"2019-03-18","kind":"purchase","acquired":true,"shares":6666667,"price":1.5,"value":10000000.5,"ownership":{"direct":false,"nature":"see fn"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, \"QVT\"), may be deemed to have beneficial ownership over the 105,952,381 Common Shares held by Roivant Sciences Ltd. (\"Roivant\") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws, namely, the appointment of one or more independent directors (within the meaning of that term under Roivant's bye-laws) to Roivant's board of directors."}],"balance_after":105952381,"source":{"system":"sec-edgar","filing":"0000899243-19-008356","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290166/000089924319008356/doc4.xml","form_type":"4"}},{"id":3723226,"issuer":{"id":130622,"kind":"organization","name":"Sio Gene Therapies Inc.","symbol":"SIOX"},"owners":[{"id":156027,"kind":"organization","name":"QVT Associates GP LLC","position":1,"cik":"0001290166","reported_name":"QVT Associates GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":161619,"kind":"organization","name":"QVT Offshore Ltd.","position":2,"cik":"0001301801","reported_name":"QVT Offshore Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, $0.00001 par value per share","published_at":"2018-12-20T06:15:58.000Z","date":"2018-12-18","kind":"purchase","acquired":true,"shares":10000000,"price":1,"value":10000000.0,"ownership":{"direct":false,"nature":"see fn"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Offshore Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, \"QVT\"), may be deemed to have beneficial ownership over the 99,285,714 Common Shares held by Roivant  Sciences Ltd. (\"Roivant\") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws, namely, the appointment of one or more independent directors (within the meaning of that term under Roivant's bye-laws) to Roivant's board of directors."}],"balance_after":99285714,"source":{"system":"sec-edgar","filing":"0000899243-18-031450","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290166/000089924318031450/doc4.xml","form_type":"4"}},{"id":3798363,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":156027,"kind":"organization","name":"QVT Associates GP LLC","position":1,"cik":"0001290166","reported_name":"QVT Associates GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":156028,"kind":"person","name":"QVT Fund V LP","position":2,"cik":"0001543904","reported_name":"QVT Fund V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2018-10-03T17:50:59.000Z","date":"2018-10-01","kind":"purchase","acquired":true,"shares":2678571,"price":14,"value":37499994.0,"ownership":{"direct":false,"nature":"see fn"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Family Office Fund LP (f/k/a QVT Fund V LP) and QVT Associates GP LLC, the general partner of QVT Family Office Fund LP (collectively, \"QVT\"), may be deemed to have beneficial ownership over the 22,703,669 Common Shares held by Roivant Sciences Ltd. (\"Roivant\") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":22703669,"source":{"system":"sec-edgar","filing":"0000899243-18-026091","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290166/000089924318026091/doc4.xml","form_type":"4"}},{"id":3901432,"issuer":{"id":130622,"kind":"organization","name":"Sio Gene Therapies Inc.","symbol":"SIOX"},"owners":[{"id":156027,"kind":"organization","name":"QVT Associates GP LLC","position":1,"cik":"0001290166","reported_name":"QVT Associates GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":156028,"kind":"person","name":"QVT Fund V LP","position":2,"cik":"0001543904","reported_name":"QVT Fund V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, $0.00001 par value per share","published_at":"2018-06-07T08:38:07.000Z","date":"2018-06-05","kind":"purchase","acquired":true,"shares":14285714,"price":1.75,"value":24999999.5,"ownership":{"direct":false,"nature":"see fn"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Family Office Fund LP (f/k/a QVT Fund V LP) and QVT Associates GP LLC, the general partner of QVT Family Office Fund LP (collectively, \"QVT\"), may be deemed to have beneficial ownership over the 89,285,714 Common Shares held by Roivant  Sciences Ltd. (\"Roivant\") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws, namely, the appointment of one or more independent directors (within the meaning of that term under Roivant's bye-laws) to Roivant's board of directors."}],"balance_after":89285714,"source":{"system":"sec-edgar","filing":"0000899243-18-015353","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290166/000089924318015353/doc4.xml","form_type":"4"}},{"id":3969576,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":156027,"kind":"organization","name":"QVT Associates GP LLC","position":1,"cik":"0001290166","reported_name":"QVT Associates GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":156028,"kind":"person","name":"QVT Fund V LP","position":2,"cik":"0001543904","reported_name":"QVT Fund V LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Common Shares, $0.000017727 par value per share","published_at":"2018-04-04T16:29:53.000Z","date":"2018-04-02","kind":"purchase","acquired":true,"shares":1110015,"price":20.27,"value":22500004.05,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Family Office Fund LP (f/k/a QVT Fund V LP) and QVT Associates GP LLC, the general partner of QVT Family Office Fund LP (collectively, \"QVT\"), may be deemed to have beneficial ownership over the 38,341,357 Common Shares held by Roivant  Sciences Ltd. (\"Roivant\") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws, namely, the appointment of one or more independent directors (within the meaning of that term under Roivant's bye-laws) to Roivant's board of directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"(continued from Footnote 1) The filing of this statement shall not be deemed an admission that QVT or Dr. Keith Manchester is the beneficial owner of the securities reported herein for the purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of QVT and Dr. Manchester expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein."}],"balance_after":38341357,"source":{"system":"sec-edgar","filing":"0000899243-18-009452","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290166/000089924318009452/doc4.xml","form_type":"4"}},{"id":4099321,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":156027,"kind":"organization","name":"QVT Associates GP LLC","position":1,"cik":"0001290166","reported_name":"QVT Associates GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks"}},{"id":156028,"kind":"person","name":"QVT Fund V LP","position":2,"cik":"0001543904","reported_name":"QVT Fund V LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks"}}],"security":"Series A Participating Convertible Preferred Shares","published_at":"2018-01-16T13:40:56.000Z","date":"2018-01-12","kind":"purchase","acquired":true,"shares":664000,"price":100,"value":66400000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends. Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price,"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"(Continued from Footnote 1) plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (ii) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends. Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price,"},{"field":"shares","element":"transactionShares","label":"F2","text":"(Continued from Footnote 1) plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (ii) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends. Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price,"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (ii) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends. Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price,"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (ii) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends. Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price,"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Continued from Footnote 1) plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (ii) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends. Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price,"},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"(Continued from Footnote 1) plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (ii) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Preferred Shares are directly beneficially owned by Roivant. QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Fund V LP and QVT Associates GP LLC, the general partner of QVT Fund V LP (collectively, \"QVT\") may be deemed to have beneficial ownership over the 1,164,000 Preferred Shares held by Roivant Sciences Ltd. (\"Roivant\") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Preferred Shares directly held by Roivant by virtue of the governance arrangements in Roivant's bye-laws, namely the appointment of an independent director (within the meaning of that term under Roivant's bye-laws) to Roivant's board of directors. The filing of this statement shall not be deemed an admission that QVT or Dr. Keith Manchester is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from Footnote 3) Each of QVT and Dr. Manchester expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein."}],"balance_after":1164000,"derivative":{"exercise_price":7.13,"expiration_date":"2021-10-16","underlying":"Common shares, no par value","underlying_shares":13025536},"source":{"system":"sec-edgar","filing":"0000899243-18-001022","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1447028/000089924318001022/doc4.xml","form_type":"4"}},{"id":4184854,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":156027,"kind":"organization","name":"QVT Associates GP LLC","position":1,"cik":"0001290166","reported_name":"QVT Associates GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks"}},{"id":156028,"kind":"person","name":"QVT Fund V LP","position":2,"cik":"0001543904","reported_name":"QVT Fund V LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks"}}],"security":"Series A Participating Convertible Preferred Shares","published_at":"2017-10-17T13:16:01.000Z","date":"2017-10-16","kind":"purchase","acquired":true,"shares":500000,"price":100,"value":50000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends. Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment,"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"(continued from footnote 1) and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price, plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends. Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment,"},{"field":"shares","element":"transactionShares","label":"F2","text":"(continued from footnote 1) and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price, plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends. Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment,"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price, plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends. Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment,"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from footnote 1) and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price, plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends. Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment,"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(continued from footnote 1) and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price, plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends. Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment,"},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"(continued from footnote 1) and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price, plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Preferred Shares are directly beneficially owned by Roivant. QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Fund V LP and QVT Associates GP LLC, the general partner of QVT Fund V LP (collectively, \"QVT\") may be deemed to have beneficial ownership over the 500,000 Preferred Shares held by Roivant because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Preferred Shares directly held by Roivant by virtue of the governance arrangements in Roivant's bye-laws, namely the appointment of an independent director (within the meaning of that term under Roivant's bye-laws) to Roivant's board of directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(continued from footnote 2) The filing of this statement shall not be deemed an admission that QVT or Dr. Keith Manchester is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of QVT and Dr. Manchester expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein."}],"balance_after":500000,"derivative":{"exercise_price":7.13,"expiration_date":"2021-10-16","underlying":"Common shares, no par value","underlying_shares":9808386},"source":{"system":"sec-edgar","filing":"0000899243-17-024298","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1447028/000089924317024298/doc4.xml","form_type":"4"}}]}